Published in J Urol on July 01, 2002
Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3] (DHT-3) | NCT00490022
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev (2009) 9.60
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Tumor boards and the quality of cancer care. J Natl Cancer Inst (2012) 4.87
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell (2010) 3.41
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol (2009) 3.11
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol (2014) 2.52
Oxidative stress in prostate cancer. Cancer Lett (2009) 2.28
A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol (2009) 2.26
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med (2016) 2.04
Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod Toxicol (2006) 1.93
Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol (2013) 1.90
A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract (2010) 1.90
The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res (2009) 1.88
Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol (2015) 1.81
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol (2008) 1.71
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol (2012) 1.65
Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol (2003) 1.64
Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int (2008) 1.59
Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int (2009) 1.59
Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging (2005) 1.52
Breast and prostate cancer: more similar than different. Nat Rev Cancer (2010) 1.48
The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids (2007) 1.46
Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review. BMC Med (2012) 1.45
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol (2016) 1.45
TCTP is an androgen-regulated gene implicated in prostate cancer. PLoS One (2013) 1.45
Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation (2011) 1.42
New developments in the medical management of prostate cancer. Mayo Clin Proc (2010) 1.41
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene (2014) 1.31
An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther (2013) 1.31
Ligand-specific dynamics of the androgen receptor at its response element in living cells. Mol Cell Biol (2006) 1.28
ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia (2012) 1.28
Androgen receptor signaling and mutations in prostate cancer. Asian J Androl (2010) 1.27
Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer (2010) 1.26
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol (2012) 1.24
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med (2016) 1.22
Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res (2012) 1.21
Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J (2013) 1.19
Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin (2014) 1.15
Adverse events associated with hormonal therapy for prostate cancer. Rev Urol (2005) 1.14
Endocrine disruptors and prostate cancer risk. Endocr Relat Cancer (2008) 1.14
Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol (2009) 1.14
The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am (2011) 1.13
Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology (2013) 1.12
An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol (2011) 1.11
Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol Oncol (2010) 1.11
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl (2013) 1.11
Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab (2008) 1.11
Racial disparities in cancer care in the Veterans Affairs health care system and the role of site of care. Am J Public Health (2014) 1.10
Adaptation or selection--mechanisms of castration-resistant prostate cancer. Nat Rev Urol (2012) 1.10
Androgen and its receptor promote Bax-mediated apoptosis. Mol Cell Biol (2006) 1.10
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol (2007) 1.10
Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci (2014) 1.07
Targeting 5α-reductase for prostate cancer prevention and treatment. Nat Rev Urol (2011) 1.06
Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol (2007) 1.05
A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab (2010) 1.04
Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer (2010) 1.03
Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care? Curr Oncol (2012) 1.03
Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer. Clin Cancer Res (2008) 1.02
Intermittent androgen suppression for prostate cancer. Nat Rev Urol (2010) 1.01
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. Br J Cancer (2013) 1.01
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer (2009) 1.01
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate (2010) 1.00
Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. BMC Cancer (2012) 0.99
Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology (2008) 0.99
Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J Androl (2012) 0.98
Denosumab: a new option in the treatment of bone metastases from urological cancers. Onco Targets Ther (2012) 0.98
Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev Endocrinol Metab (2009) 0.97
Aggressive prostate cancer is prevented in ERαKO mice and stimulated in ERβKO TRAMP mice. Endocrinology (2012) 0.96
Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Crit Rev Oncol Hematol (2008) 0.96
Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging (2010) 0.96
Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. Clin Cancer Res (2012) 0.96
LHRH Agonists for the Treatment of Prostate Cancer: 2012. Rev Urol (2012) 0.96
Treatment of localized prostate cancer: when is active surveillance appropriate? Nat Rev Clin Oncol (2010) 0.96
Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr Relat Cancer (2010) 0.95
Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Int J Biol Sci (2014) 0.95
The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol (2003) 0.95
Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk. Cancer Epidemiol (2012) 0.95
Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. Int J Clin Oncol (2005) 0.94
A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab (2008) 0.94
Prostate cancer-from steroid transformations to clinical translation. Nat Rev Urol (2012) 0.93
Hormonal therapy. Int J Clin Oncol (2007) 0.93
A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors. Int J Endocrinol (2013) 0.93
Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer? Front Oncol (2014) 0.93
Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells. Cancer Lett (2011) 0.93
Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Med (2014) 0.93
Impact of androgen deprivation therapy on sexual function. Asian J Androl (2012) 0.92
Androgen regulation of the androgen receptor coregulators. BMC Cancer (2008) 0.92
Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. J Steroid Biochem Mol Biol (2013) 0.92
Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol (2010) 0.91
Innovations in the systemic therapy of prostate cancer. Nat Rev Clin Oncol (2009) 0.91
Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol (2010) 0.91
ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk. Neoplasia (2006) 0.91
Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol (2002) 2.37
Ultrasound can accurately guide gastrostomy tube replacement and confirm proper tube placement at the bedside. J Emerg Med (2008) 0.78